Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10930611 | Cytotherapy | 2014 | 21 Pages |
Abstract
Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Usanarat Anurathapan, Ann M. Leen, Malcolm K. Brenner, Juan F. Vera,